熱門資訊> 正文

Genentech获得狼疮药物obinutuzumab批准

2025-10-21 05:57

The US FDA approved Gazyva (obinutuzumab), a lupus nephritis treatment from Roche-owned (OTCQX:RHHBY) Genentech.
Gazyva is given via infusion four times in the first year, followed by twice a year after that.
In a phase 3 study, 46.4% of patients on Gazyva and standard therapy achieved a complete renal response vs. 33.1% on standard therapy alone.
The European Medicines Agency’s Committee for Medicinal Products for Human Use has issued a positive opinion recommending approval of Gazyva

More on Roche Holding

Roche's Giredestrant: A Ray Of Hope On A Cloudy Horizon?
Roche Holding AG (RHHBY) Discusses On Pharma Day 2025 (Transcript)
Roche Holding AG (RHHBY) Special Call - Slideshow
Roche breast cancer drug improves survival of up to 62% in late-stage trial
Sanofi and Insmed among winners of EU drug recommendations this week

推薦文章

風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。